Lotus Pharmaceutical
Market Cap
NT$17.3b
Last Updated
2021/01/26 08:42 UTC
Data Sources
Company Financials +
Executive Summary
Lotus Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells medicines in Taiwan, Korea, the United States, and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Proven track record and fair value.
Similar Companies
Share Price & News
How has Lotus Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1795 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 1795's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
-4.3%
1795
-0.9%
TW Pharmaceuticals
2.0%
TW Market
1 Year Return
-32.3%
1795
31.8%
TW Pharmaceuticals
31.2%
TW Market
Return vs Industry: 1795 underperformed the TW Pharmaceuticals industry which returned 31.8% over the past year.
Return vs Market: 1795 underperformed the TW Market which returned 31.2% over the past year.
Shareholder returns
| 1795 | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.3% | -0.9% | 2.0% |
| 30 Day | -13.3% | -8.0% | 10.6% |
| 90 Day | -12.9% | -15.2% | 22.8% |
| 1 Year | -32.3%-32.3% | 34.1%31.8% | 35.8%31.2% |
| 3 Year | 42.7%42.7% | 39.5%31.9% | 58.3%40.5% |
| 5 Year | 7.5%7.5% | 10.5%2.0% | 133.0%92.1% |
Long-Term Price Volatility Vs. Market
How volatile is Lotus Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?3 weeks ago | Simply Wall St
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?1 month ago | Simply Wall St
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With EaseValuation
Is Lotus Pharmaceutical undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1795 (NT$70.4) is trading below our estimate of fair value (NT$837.79)
Significantly Below Fair Value: 1795 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1795 is poor value based on its PE Ratio (20.2x) compared to the TW Pharmaceuticals industry average (17.9x).
PE vs Market: 1795 is poor value based on its PE Ratio (20.2x) compared to the TW market (18.6x).
Price to Earnings Growth Ratio
PEG Ratio: 1795 is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: 1795's PB Ratio (2.1x) is in line with the TW Pharmaceuticals industry average.
Next Steps
Future Growth
How is Lotus Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
33.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1795's forecast earnings growth (33.2% per year) is above the savings rate (0.8%).
Earnings vs Market: 1795's earnings (33.2% per year) are forecast to grow faster than the TW market (18.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1795's revenue (6.8% per year) is forecast to grow slower than the TW market (11.2% per year).
High Growth Revenue: 1795's revenue (6.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1795's Return on Equity is forecast to be low in 3 years time (11.7%).
Next Steps
Past Performance
How has Lotus Pharmaceutical performed over the past 5 years?
58.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1795 has high quality earnings.
Growing Profit Margin: 1795's current net profit margins (8.2%) are higher than last year (7.3%).
Past Earnings Growth Analysis
Earnings Trend: 1795 has become profitable over the past 5 years, growing earnings by 58.6% per year.
Accelerating Growth: 1795's earnings growth over the past year (42.2%) is below its 5-year average (58.6% per year).
Earnings vs Industry: 1795 earnings growth over the past year (42.2%) exceeded the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: 1795's Return on Equity (10.3%) is considered low.
Next Steps
Financial Health
How is Lotus Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 1795's short term assets (NT$5.8B) exceed its short term liabilities (NT$4.0B).
Long Term Liabilities: 1795's short term assets (NT$5.8B) do not cover its long term liabilities (NT$6.3B).
Debt to Equity History and Analysis
Debt Level: 1795's debt to equity ratio (79.7%) is considered high.
Reducing Debt: 1795's debt to equity ratio has increased from 55.7% to 79.7% over the past 5 years.
Debt Coverage: 1795's debt is well covered by operating cash flow (22.8%).
Interest Coverage: 1795's interest payments on its debt are well covered by EBIT (4.6x coverage).
Balance Sheet
Next Steps
Dividend
What is Lotus Pharmaceutical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1795's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1795's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1795's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1795's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1795's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.0yrs
Average management tenure
CEO
Petar Vazharov
3yrs
Tenure
NT$12,828,000
Compensation
Mr. Petar Antonov Vazharov is Executive Vice President of the Asia Pacific Region of Alvogen Group. He is General Manager of Alvogen Korea Holdings Ltd. He is a Director of Alvogen Korea Co., Ltd., Alvogen...
CEO Compensation Analysis
Compensation vs Market: Petar's total compensation ($USD457.95K) is about average for companies of similar size in the TW market ($USD442.53K).
Compensation vs Earnings: Insufficient data to compare Petar's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 3yrs | NT$12.83m | no data | |
| Chief Financial Officer | 4.17yrs | NT$5.19m | no data | |
| VP / Deputy General Manager of Strategy & Finance | 3yrs | NT$10.35m | no data | |
| Country Manager | 3yrs | NT$5.82m | no data | |
| Vice President of Supply Chain & Operations | 1.5yrs | no data | 0.0057% NT$ 990.5k | |
| Corporate Finance & Regional Investor Relations Director | no data | no data | no data | |
| Chief Executive Officer of Norwich Clicial Services | no data | no data | no data | |
| Vice President | no data | no data | no data | |
| Strategic Consultant | 4.08yrs | no data | no data |
3.0yrs
Average Tenure
Experienced Management: 1795's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 3yrs | NT$12.83m | no data | |
| Independent Director | 5.75yrs | NT$898.00 | no data | |
| Chairman | 2.08yrs | no data | no data | |
| Director | 6.33yrs | no data | no data | |
| Director | 1.58yrs | no data | no data | |
| Director | 6.33yrs | no data | no data | |
| Director | 3.5yrs | no data | no data | |
| Independent Director | 6.33yrs | NT$750.00 | no data | |
| Independent Director | 4.58yrs | NT$640.00 | 0.0029% NT$ 494.4k | |
| Director | 1.83yrs | no data | no data |
5.2yrs
Average Tenure
Experienced Board: 1795's board of directors are considered experienced (5.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Lotus Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Lotus Pharmaceutical Co., Ltd.
- Ticker: 1795
- Exchange: TSEC
- Founded: 1966
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$17.347b
- Shares outstanding: 245.35m
- Website: https://www.lotuspharm.com.tw
Number of Employees
Location
- Lotus Pharmaceutical Co., Ltd.
- No. 277 Song Ren Road
- Xin Yi District
- Taipei
- 110
- Taiwan
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 1795 | TSEC (Taiwan Stock Exchange) | Yes | Share Capital | TW | TWD | Aug 2014 |
Biography
Lotus Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells medicines in Taiwan, Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of o...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/26 08:42 |
| End of Day Share Price | 2021/01/26 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.